Etomoxir, an inhibitor of the carnitine-dependent transporter CPT1 (also known as CPT1A) and FAO, was able to eradicate ∼50% of quiescent leukaemia SCs in primary human myeloid leukaemia samples, and sensitize leukaemia cells to apoptosis-inducing agents in a murine model (Samudio et al., 2010) (Fig. 2). The gene discussed is CPT1A; the disease is leukemia.